Enhancing cytotoxicity of immunotoxins in AML

Naval Daver; Farhad Ravandi

doi:10.1182/blood-2016-04-708214

Enhancing cytotoxicity of immunotoxins in AML

Naval Daver, Farhad Ravandi

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

In this issue of Blood, Vasu et al show that a novel, Fc-engineered CD33 antibody, BI 836858, promotes natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) with in vitro activity against both acute myeloid leukemia (AML) cell lines and primary AML blasts.

Original language	English (US)
Pages (from-to)	2787-2788
Number of pages	2
Journal	Blood
Volume	127
Issue number	23
DOIs	https://doi.org/10.1182/blood-2016-04-708214
State	Published - Jun 9 2016

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-04-708214

Cite this

@article{142e3100b9684d85809a33373f5f93ce,

title = "Enhancing cytotoxicity of immunotoxins in AML",

abstract = "In this issue of Blood, Vasu et al show that a novel, Fc-engineered CD33 antibody, BI 836858, promotes natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) with in vitro activity against both acute myeloid leukemia (AML) cell lines and primary AML blasts.",

author = "Naval Daver and Farhad Ravandi",

note = "Publisher Copyright: {\textcopyright} 2016 by The American Society of Hematology.",

year = "2016",

month = jun,

day = "9",

doi = "10.1182/blood-2016-04-708214",

language = "English (US)",

volume = "127",

pages = "2787--2788",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - Enhancing cytotoxicity of immunotoxins in AML

AU - Daver, Naval

AU - Ravandi, Farhad

PY - 2016/6/9

Y1 - 2016/6/9

N2 - In this issue of Blood, Vasu et al show that a novel, Fc-engineered CD33 antibody, BI 836858, promotes natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) with in vitro activity against both acute myeloid leukemia (AML) cell lines and primary AML blasts.

AB - In this issue of Blood, Vasu et al show that a novel, Fc-engineered CD33 antibody, BI 836858, promotes natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) with in vitro activity against both acute myeloid leukemia (AML) cell lines and primary AML blasts.

UR - http://www.scopus.com/inward/record.url?scp=84974624934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974624934&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-04-708214

DO - 10.1182/blood-2016-04-708214

M3 - Comment/debate

C2 - 27282944

AN - SCOPUS:84974624934

SN - 0006-4971

VL - 127

SP - 2787

EP - 2788

JO - Blood

JF - Blood

IS - 23

ER -

Enhancing cytotoxicity of immunotoxins in AML

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this